Access brought to you by: LOCKSS

Hepatology Clinical Trials

Combination DCV/SOF is Effective in Achieving Sustained Response in Patients with HCV GT-3
SOF Plus GS-5816 Effective in Noncirrhotic Patients Infected with HCV GT-3: ELECTRON-2 Final Results
Sebelipase Alfa Normalizes ALT and Multiple other Disease-Related Abnormalities in Patients with LAL-D
Uniform Downstaging Protocol Produces Excellent Posttransplantation Outcomes in HCC
SOF Plus GS-5816 Effective in Noncirrhotic, Treatment-Naïve Patients Infected with HCV Genotypes 1 to 6
Terlipressin and Albumin Combination Therapy Improves Renal Function in HRS-1
Direct-Acting Antiviral Therapy Produces High SVR12 in HCV GT-1 Cirrhotic Patients Regardless of Baseline Characteristics
Myrcludex B Therapy Reduced HBV DNA and HDV RNA in Phase 2a Clinical Trial
SVR after Treatment of HCV Genotype 1a with ABT-450/Ritonavir, Ombitasvir, and Dasabuvir is Enhanced by RBV in Noncirrhotic Patients and by Extension of Duration in Cirrhotic Patients
HCV—Infected Patients with Compensated Cirrhosis Benefit from 12-Week, Once-Daily, Oral Combination of LDV and SOF

Pages